Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Q-linea AB (publ)
  6. News
  7. Summary
    QLINEA   SE0011527845

Q-LINEA AB (PUBL)

(QLINEA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Q linea : signs first commercial evaluation contract for ASTar

10/15/2021 | 02:01am EST

Q-linea AB (publ) (OMX: QLINEA) – Q-linea announces today that the first commercial evaluation contract has been signed for ASTar® with a Swedish regional hospital.

The ASTar Instrument and ASTar BC G- Kit offer the broadest combination of antimicrobials and dilution ranges in a single analysis for Gram-negative bacteria. The test enables the analysis of both fastidious and non-fastidious bacteria, for rapid fully automatic and comprehensive results that support optimal treatment decisions.

“We are delighted to announce that we now have received the first commercial evaluation contract in direct connection with the official launch of ASTar. We are very positive about the future.”, says Jonas Jarvius, CEO at Q-linea.

ASTar Instrument and ASTar BC G- Kit is CE-marked but not FDA 510(k)-cleared and not available for sale in the U.S.

© Modular Finance, source Nordic Press Releases

All news about Q-LINEA AB (PUBL)
11/04Q-linea AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septemb..
CI
10/28Invitation to presentation of Q-linea's Interim report Q3-2021 on November 4, 2021
AQ
10/15Q LINEA : signs first commercial evaluation contract for ASTar
AQ
10/15Q-linea Signs First Commercial Evaluation Contract for ASTar
CI
10/07Q LINEA : ASTar launched in Europe
AQ
10/06Q LINEA : is taking the next step in the clinical study for the US market
AQ
10/06Q-linea AB Starts Reproducibility Part of the Clinical Study with ASTar for US 510 (K) ..
CI
07/15Q-Linea AB Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/08Q LINEA : Invitation to presentation of Q-linea's Interim report Q2-2021 on July 15, 2021
AQ
06/30Q LINEA : Change in the number of shares and votes in Q-linea AB
AQ
More news
Financials
Sales 2021 41,0 M 4,51 M 4,51 M
Net income 2021 -192 M -21,1 M -21,1 M
Net cash 2021 64,3 M 7,08 M 7,08 M
P/E ratio 2021 -16,3x
Yield 2021 -
Capitalization 3 196 M 351 M 352 M
EV / Sales 2021 76,4x
EV / Sales 2022 9,09x
Nbr of Employees 124
Free-Float 87,3%
Chart Q-LINEA AB (PUBL)
Duration : Period :
Q-linea AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends Q-LINEA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 109,40 SEK
Average target price 185,00 SEK
Spread / Average Target 69,1%
EPS Revisions
Managers and Directors
Jonas Sven Peter Jarvius President & Chief Executive Officer
Anders Lundin Chief Financial Officer & Head-Investor Relations
Erika Elisabeth Kjellberg-Eriksson Chairman
Tiziana di Martino Chief Medical Officer
Nils-Peter Kristensen Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
Q-LINEA AB (PUBL)-35.65%351
SARTORIUS AG49.28%42 386
BIOTAGE AB (PUBL)89.21%1 906
REVENIO GROUP OYJ9.24%1 652
VAREX IMAGING CORPORATION76.68%1 162
CELLAVISION AB (PUBL)15.90%932